Ozzy Osbourne and Parkinson's disease: from darkness to awareness
Luis F. Fabrini Paleare, José Luiz Pedroso, Flávia de Paiva Santos Rolim, Natália R. Karpejany, Carlos Henrique Ferreira Camargo, Hélio A. G. Teive, Gustavo L. FranklinAbstract
Ozzy Osbourne, the legendary frontman of Black Sabbath, publicly revealed his diagnosis of Parkinson's disease (PD) in 2020, offering visibility to a complex neurodegenerative condition. His case, later linked to a mutation in the PARK2 (parkin) gene, presented atypically with a later age of onset, contributing to ongoing discussions about the phenotypic variability of genetic forms of PD. Beyond medical narratives, Osbourne's openness and philanthropy—culminating in a benefit concert that raised $190 million for Parkinson's and pediatric charities—played a transformative role in destigmatizing the disease. This article explores the scientific and social impact of Osbourne's disclosure, highlighting the role of PARK2 in mitochondrial homeostasis, synaptic integrity, and tumor suppression. We also examine his pursuit of experimental stem cell therapy, discussing its scientific basis, ethical considerations, and current clinical research landscape.